Advertisement

Annals of Hematology

, Volume 96, Issue 3, pp 441–448 | Cite as

Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic

  • Ariana Berenson
  • Suzie Vardanyan
  • Michael David
  • James Wang
  • Nika Manik Harutyunyan
  • Jillian Gottlieb
  • Ran Halleluyan
  • Tanya M. Spektor
  • Kyle A. Udd
  • Shahrooz Eshaghian
  • Youram Nassir
  • Benjamin Eades
  • Regina Swift
  • James R. BerensonEmail author
Original Article

Abstract

Despite recent advances made in its treatment, multiple myeloma (MM) remains an incurable B cell malignancy. Thus, the objective for treating these patients is to prolong overall survival (OS) and preserve patients’ quality of life. We have analyzed data from 264 consecutive MM patients who had their initial visit between July 1, 2004 and December 1, 2014 and have received treatment in a single clinic specializing in MM. We determined their progression-free survival (PFS, OS, and 5-year OS). The PFS for frontline (n = 165 treatments), salvage (n = 980), and all treatments (n = 1145) were 13.9, 4.6, and 5.5 months, respectively. The median OS of all patients was 98 months with a 5-year survival of 74%. The results of this study show a marked improvement in OS for unselected MM patients compared with historical data. There were no significant differences in OS between patients with different International Staging System (ISS) stages. Younger patients (<65 years old) showed a longer OS. The results of this study should help physicians predict outcomes for MM patients and be encouraging for patients with this B cell malignancy.

Keywords

Multiple myeloma Overall survival Progression-free survival 

Notes

Compliance with ethical standards

This study was conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Conflict of interest

Dr. Berenson is a consultant and receives honoraria and research funding from Takeda, Onyx-Amgen, Amgen, Janssen, Celgene, and Bristol-Meyers-Squibb. Ms. Swift receives honoraria from Celgene, Takeda-Millennium, Bristol-Meyers-Squibb, and Onyx-Amgen.

References

  1. 1.
    American Cancer Society (2016) http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf Cancer facts & figures 2016. American Cancer Society, AtlantaGoogle Scholar
  2. 2.
    Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516–2520. doi: 10.1182/blood-2007-10-116129 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364(11):1046–1060. doi: 10.1056/NEJMra1011442 CrossRefPubMedGoogle Scholar
  4. 4.
    Pulte D, Jansen L, Castro FA, Emrich K, Katalinic A, Holleczek B, Brenner H (2015) Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. Br J Haematol 171(2):189–196. doi: 10.1111/bjh.13537 CrossRefPubMedGoogle Scholar
  5. 5.
    Brenner H, Gondos A, Pulte D (2008) Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111(5):2521–2526. doi: 10.1182/blood-2007-08-104984 CrossRefPubMedGoogle Scholar
  6. 6.
    Turesson I, Velez R, Kristinsson SY, Landgren O (2010) Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol Off J Am Soc Clin Oncol 28(5):830–834. doi: 10.1200/JCO.2009.25.4177 CrossRefGoogle Scholar
  7. 7.
    Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N, Michali E, Zomas A, Katodritou E, Gika D, Pouli A, Christoulas D, Roussou M, Kartasis Z, Economopoulos T, Dimopoulos MA (2009) Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 23(6):1152–1157. doi: 10.1038/leu.2008.402 CrossRefPubMedGoogle Scholar
  8. 8.
    Ríos-Tamayo R, Sánchez MJ, Puerta JM, Sáinz J, Chang DY, Rodríguez T, Lopez P, de Pablos JM, Bavarro P, de Veas JL, Romero A, Garrido P, Moratalla L, Alarcon-Payer C, Lopez-Fernandez E, Gonzalez PA, Jimenez-Moleon JJ, Callega-Hernandez MA, Jurado M (2015) Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution. Cancer Epidemiol 39(5):693–699. doi: 10.1016/j.canep.2015.08.002 CrossRefPubMedGoogle Scholar
  9. 9.
    Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28(5):1122–1128. doi: 10.1038/leu.2013.313 CrossRefPubMedGoogle Scholar
  10. 10.
    Pozzi S, Marcheselli L, Bari A, Liardo EV, Marcheselli R, Luminari S, Quaresima M, Cirilli C, Ferri P, Frederico M, Sacchi S (2013) Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br J Haematol 163(1):40–46. doi: 10.1111/bjh.12465 CrossRefPubMedGoogle Scholar
  11. 11.
    Mey UJ, Leitner C, Driessen C, Cathomas R, Klingbiel D, Hitz F (2015) Improved survival of older patients with multiple myeloma in the era of novel agents. Hematological Oncology. doi: 10.1002/hon.2205 PubMedGoogle Scholar
  12. 12.
    Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23(15):3412–3420. doi: 10.1200/JCO.2005.04.242 CrossRefGoogle Scholar
  13. 13.
    Bataille R, Annweiler C, Beauchet O (2013) Multiple myeloma international staging system: “staging” or simply “aging” system? Clinical Lymphoma Myeloma & Leukemia 13(6):635–637. doi: 10.1016/j.clml.2013.07.003 CrossRefGoogle Scholar
  14. 14.
    Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR (2009) Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol 46(2):110–117. doi: 10.1053/j.seminhematol.2009.02.004 CrossRefPubMedGoogle Scholar
  15. 15.
    Martinez López J, Jurado M, Clavero Sánchez ME, Lopez Jiménez F, Paciello Coronel ML, Garcia Fernández JR, de la Torre YM, Lopez Berenguel F, Leyva Ferrer R, Sainz Perez J, Molina Portillo E, Sanchez Perez MJ, de Pablos Gallego JM, Lopez Garrido P, Jimenez Moleon JJ, Lopez de Lacalle A, Lahuerta Palacios JJ. (2013) Prognostic impact of comorbidity in multiple myeloma. Blood, 122(21): Abstract 5340. (American Society of Hematology Annual Meeting Abstracts).Google Scholar
  16. 16.
    Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA, Crowley J, Chen H, Berenson JR (2012) Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol 158(6):727–738. doi: 10.1111/j.1365-2141.2012.09241.x CrossRefPubMedGoogle Scholar
  17. 17.
    de Mel S, Lim SH, Tung ML, Chng WJ (2014) Implications of heterogeneity in multiple myeloma. Biomed Res Int v.2014:232546. doi: 10.1155/2014/232546 Google Scholar
  18. 18.
    Bergsagel PL, Mateos MV, Gutierrez CN, Rajkumar V, San Miguel JF (2013) Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 131(6):884–892CrossRefGoogle Scholar
  19. 19.
    Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turresson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467–1473. doi: 10.1038/sj.leu.2404284 CrossRefPubMedGoogle Scholar
  20. 20.
    Paiva B, van Dongen JJ, Orfao A (2015) New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 125(20):3059–3068. doi: 10.1182/blood-2014-11-568907 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, Garcia-Laraña J, Martinez-Martinez R, Hernandez-Garcia MT, Carrera D, Besalduch J, de Arriba F, Ribera JM, Escoda L, Hernandez-Ruiz B, Garcia-Frade J, Rivas-Gonzalez C, Alegre A, Blade J, San Miguel JF (2008) Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26(35):5775–5782. doi: 10.1200/JCO.2008.17.9721 CrossRefGoogle Scholar
  22. 22.
    Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, Genuardi M, Romano A, Liberati AM, Siniscalchi A, Petrucci MT, Nozzoli C, Patriarca F, Offidani M, Ria R, Omede P, Bruno B, Passera R, Musto P, Boccadoro M, Sonneveld P, Palumbo A (2011) Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117(11):3025–3031. doi: 10.1182/blood-2010-09-307645 CrossRefPubMedGoogle Scholar
  23. 23.
    Migkou M, Kastritis E, Roussou M, Gkotzamanidou M, Gavriatopoulou M, Nikitas N, Mparmparoussi D, Matsouka C, Gika D, Terpos E, Dimopoulos MA (2011) Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy. Eur J Haematol 87(4):323–329. doi: 10.1111/j.1600-0609.2011.01659.x CrossRefPubMedGoogle Scholar
  24. 24.
    Rajan AM, Rajkumar SV (2015) Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer Journal 5:e365. doi: 10.1038/bcj.2015.92 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23(1):3–9. doi: 10.1038/leu.2008.291 CrossRefPubMedGoogle Scholar
  26. 26.
    Fujisawa M, Suehara Y, Fukumoto K, Takeuchi M, Matsue K (2016) Changes in survival rate of multiple myeloma after the introduction of bortezomib: a single institutional experience over 20 years. Ann Hematol 95(1):63–72. doi: 10.1007/s00277-015-2522-9 CrossRefPubMedGoogle Scholar
  27. 27.
    Pulte D, Gondos A, Brenner H (2011) Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist 16(11):1600–1603. doi: 10.1634/theoncologist.2011-0229 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J (2008) Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 111(8):4039–4047. doi: 10.1182/blood-2007-03-081018 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ (2012) A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26(2):349–355. doi: 10.1038/leu.2011.204 CrossRefPubMedGoogle Scholar
  30. 30.
    Gastinne T, Leleu X, Duhamel A, Moreau AS, Franck G, Andrieux J, Lai JL, Coiteux V, Yakoub-Agha I, Bauters F, Harousseau JL, Zandecki M, Facon T (2007) Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I. Eur J Haematol 79(4):297–304. doi: 10.1111/j.1600-0609.2007.00915.x CrossRefPubMedGoogle Scholar
  31. 31.
    Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagrione S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 33(26):2863–2869. doi: 10.1200/JCO.2015.61.2267 CrossRefGoogle Scholar
  32. 32.
    Harousseau JL, Attal M, Avet-Loiseau H (2009) The role of complete response in multiple myeloma. Blood 114(15):3139–3146. doi: 10.1182/blood-2009-03-201053 CrossRefPubMedGoogle Scholar
  33. 33.
    Niesvizky R, Richardson PG, Rajkumar SV, Coleman M, Rosiñol L, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Boral AL, Esseltine DL, Anderson KC, Bladé J (2008) The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 143(1):46–53. doi: 10.1111/j.1365-2141.2008.07303.x CrossRefPubMedGoogle Scholar
  34. 34.
    Lonial S, Kaufman JL (2012) The era of combination therapy in myeloma. J Clin Oncol 30(20):2434–2436. doi: 10.1200/JCO.2011.40.6967 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Ariana Berenson
    • 1
  • Suzie Vardanyan
    • 1
  • Michael David
    • 1
  • James Wang
    • 1
    • 2
  • Nika Manik Harutyunyan
    • 1
  • Jillian Gottlieb
    • 1
  • Ran Halleluyan
    • 1
  • Tanya M. Spektor
    • 3
  • Kyle A. Udd
    • 1
    • 2
  • Shahrooz Eshaghian
    • 1
  • Youram Nassir
    • 2
  • Benjamin Eades
    • 2
  • Regina Swift
    • 2
  • James R. Berenson
    • 1
    • 2
    • 3
    Email author
  1. 1.Institute for Myeloma & Bone Cancer ResearchWest HollywoodUSA
  2. 2.James R. Berenson, MD, Inc., Institute for Myeloma & Bone Cancer ResearchWest HollywoodUSA
  3. 3.OncotherapeuticsWest HollywoodUSA

Personalised recommendations